Updated October 2026 22 min read

Botox Consent Forms for Med Spas: What Must Be Included

A weak Botox consent form is one of the most common liability gaps in aesthetic practices. What makes neurotoxin consent different from consent for any other treatment, who has to obtain it, and whether a template can actually get you there.

In short

A compliant Botox consent form names the specific product, discloses off-label treatment areas, states the FDA Boxed Warning and material risks including ptosis and asymmetry, sets onset and duration expectations, states the touch-up policy, and is signed before every treatment episode by the patient and the practitioner who conducted the discussion — not once at intake. Who may obtain that consent varies by state. A downloaded template can give you the structure, but it is not a finished compliance document until your medical director and counsel have reviewed it against your products, protocols, and state rules.

Informed consent is the legal and ethical foundation of every medical procedure — including Botox. Yet consent forms remain one of the most commonly deficient documents in aesthetic medicine malpractice cases.

Too many med spas use generic, downloaded consent templates that fail to disclose the FDA's Boxed Warning, omit off-label treatment areas, or don't clearly connect the consent to a specific treatment session. When a complication occurs and a patient claims they "didn't know about the risks," your consent form is your primary defense.

This guide is neurotoxin-specific: what makes Botox and the other neuromodulators different from every other consent form in your library, exactly what the form must include, who is allowed to obtain that consent, and whether a downloaded template can actually get you there. General consent law — the legal standard for valid consent, photo and marketing authorization, record retention, and who can sign for a minor — applies the same way to every treatment a med spa offers, and we cover it once, in full, in our med spa consent forms guide. This page links to it rather than repeating it.

What Makes Neurotoxin Consent Different From Consent for Any Other Treatment?

Neurotoxin consent carries disclosures that don't apply to most other services: a federally mandated warning about effects spreading beyond the injection site, routine use outside the product's labeled indication, and a result that fades on a predictable timeline and is commonly re-treated. A filler consent or a peel consent doesn't need any of that; filler carries its own disclosure burden, set out in our dermal filler consent form guide, and deoxycholic acid under the chin carries a nerve-injury and swelling burden of its own, covered in our Kybella consent form template. A Botox consent form that was built by copying a generic aesthetic-consent template usually drops all three.

  • Off-label treatment areas. A meaningful share of routine neurotoxin injection is off-label — masseter reduction, neck bands, a gummy smile, hyperhidrosis outside the labeled sites. The form has to say so, by area, rather than treating "Botox" as a single labeled use.
  • Spread and ptosis risk disclosure. The Boxed Warning about distant spread of toxin effect is specific to botulinum toxin products and doesn't appear on a filler or laser consent. Ptosis — eyelid or brow drooping — is the complication patients fear and recognize fastest, and it needs its own line, not a buried mention inside a general "side effects may include" paragraph.
  • Onset and duration expectations. Patients routinely show up unhappy at day three because they expected an immediate result. The consent should set out that full effect takes time to appear and fades on its own over a period of months, so the timeline is something the patient agreed to in writing, not something they're told for the first time when they call to complain.
  • Touch-up policy. Neurotoxin is the service most likely to generate a two-to-three-week follow-up visit for a small correction. Whether that visit is included in the original price, how long the window stays open, and what counts as a touch-up versus a new treatment should be on the form, not left to whoever answers the phone that day.
  • Repeat-treatment consent. Neurotoxin patients return every few months for years. A consent program built for a one-time procedure — sign once, file it, forget it — doesn't fit a service where the same patient is back on your schedule before the form's assumptions are even tested.

Informed Consent vs. a Signed Consent Form

Informed consent is the conversation; the signed form is the record that it happened. Our consent forms guide walks through the four elements courts and boards evaluate it against — capacity, disclosure, voluntariness, and documentation — and that standard doesn't change by treatment type, so we won't repeat it here.

What changes for neurotoxin is the content of the disclosure itself. "Adequate information about the proposed treatment" means, specifically, the product being used, the areas being treated and whether any are off-label, the Boxed Warning, the risks in the list below, and the onset and duration the patient should expect. A signature on a form that never said any of that is a signature, not informed consent — and it's the gap a plaintiff's attorney or a board investigator checks first.

What Must a Botox Consent Form Include?

A compliant Botox consent form names the specific neurotoxin product, discloses the treatment areas including any off-label use, states the FDA Boxed Warning and the common and rare risks, sets realistic onset and duration expectations and the touch-up policy, documents contraindication screening, and closes with signed, dated acknowledgment from the patient and the practitioner who conducted the discussion.

  • Patient name, date of birth, and date of this treatment episode
  • Specific product by brand name — Botox, Dysport, Xeomin, Jeuveau, Daxxify — never a generic "neurotoxin" or "Botox-type" label
  • Treatment areas, with any off-label area named explicitly rather than folded into a general areas list
  • The FDA Boxed Warning on distant spread of toxin effect, in full
  • Common risks: bruising, swelling, redness, headache, asymmetry, ptosis, brow heaviness
  • Onset and duration expectations for this product
  • The touch-up policy — timing, what qualifies, and whether it's included in the price
  • Contraindication and health-history screening relevant to neurotoxin specifically
  • Pre- and post-treatment instructions the patient was given
  • Reference to separate photography and marketing-use authorization where applicable
  • Patient signature with date and time, and the signature of the practitioner who obtained consent

FDA-Required Boxed Warning Disclosure

This is the element most commonly missing from generic consent forms. The FDA requires a Boxed Warning — the highest-level FDA safety warning — for all botulinum toxin products. Your consent form must disclose this warning:

"Distant spread of toxin effect: Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death."

Simply listing "headache and bruising" as the only risks on a consent form, without this Boxed Warning, is legally inadequate.

Common Side Effects and Risks

The consent form should include, consistent with how we describe these same events in our Botox complications guide:

  • Injection site reactions: Bruising, swelling, redness, pain, and tenderness, generally resolving within days to about two weeks
  • Headache or transient flu-like symptoms: Generally short-lived
  • Asymmetry: Uneven results between sides
  • Ptosis: Drooping of the eyelid or brow — temporary and self-limited, typically resolving within weeks and occasionally lasting as long as the toxin's own effect
  • Brow heaviness: A heavy brow sensation, especially with forehead treatment, often confused by patients with true eyelid ptosis
  • Undercorrection or overcorrection: Results may not achieve the desired effect; additional treatment or time may be needed
  • Temporary nature of results: The effect fades on its own over time, and regular maintenance treatment is needed to sustain it

Contraindication Screening and Pre-Treatment Health History

The consent form should include a checklist of conditions that may affect treatment:

  • Known allergy or sensitivity to botulinum toxin or albumin (egg allergy)
  • Neuromuscular disease (ALS, myasthenia gravis, Lambert-Eaton syndrome) — absolute contraindications
  • Current pregnancy or breastfeeding (Botox is not approved in pregnancy)
  • Current anticoagulant use (increases bruising risk)
  • Recent other botulinum toxin treatments (risk of cumulative effect)
  • Active skin infection in the treatment area
  • Current medications that may interact (aminoglycosides, certain muscle relaxants)
Need a complete Botox SOP with consent templates?

Our Injectables Protocol Kit includes a fully written Botox SOP with informed consent templates, pre-treatment assessment, injection protocols, complication management, and aftercare instructions.

Get the Injectables Protocol Kit — $297

Pre-Treatment and Post-Treatment Instructions

Consent documentation should confirm the patient received instructions for:

  • Pre-treatment: Avoid blood thinners (aspirin, ibuprofen, fish oil) for 7–10 days if possible; arrive with a clean face (no makeup); disclose all supplements
  • Post-treatment: Do not rub or massage treated areas for 24 hours; remain upright for 4 hours post-injection; avoid vigorous exercise for 24 hours; do not apply heat (sauna, hot yoga) for 24–48 hours

Photography and Acknowledgment

Clinical photography for the record is covered by your general consent to treat; using an identifiable image in marketing needs a separate, revocable authorization. That distinction, and exactly what the marketing authorization must say, is covered in full in our consent forms guide's before-and-after photo consent section — don't rebuild that logic inside your Botox form.

The Botox form itself must still include explicit patient attestation that the patient read and understood the information, had questions answered to their satisfaction, voluntarily consents to treatment, and understands they may withdraw consent at any time before treatment begins. Required fields: patient signature, date and time, and the name and signature of the practitioner who reviewed the consent with the patient.

Who Must Obtain Neurotoxin Consent — Ordering Practitioner vs. Injector?

The duty to disclose risks and obtain informed consent belongs to the practitioner who makes the treatment decision — the ordering physician, nurse practitioner, or physician assistant, within the scope their state allows. The person who physically performs the injection is not automatically the same person who is permitted to have that conversation, and the two roles can be held by different people depending on your state's supervision and delegation structure.

This is where neurotoxin consent gets genuinely state-dependent, and it's also where templates fail quietly: a form built in one state's delegation model, with a single signature line for "injector," doesn't show that the ordering practitioner's disclosure happened at all if that practitioner never saw the patient. An esthetician or medical assistant handing over a form, answering "what are the risks?" themselves, and collecting the signature has not obtained informed consent, whatever the signature line says.

The fix is structural: the form needs separate lines for the practitioner who conducted the consent discussion and the practitioner who will inject (where those differ), and your practice's delegation chart needs to match what the form implies. Because who may order, who may inject, and who may supervise varies by state and by license type, we don't attempt a single national answer here. See our regulations by state hub for the state-specific supervision and delegation picture, and our guide on who can inject Botox in the United States for the breakdown by role and license.

This also means a single-location practice and a multi-site practice can need different consent workflows for the same patient population. A medical director who orders treatment for patients across several locations without examining each one in person has to be confident that whatever evaluation process stands in for that visit still produces a genuine disclosure conversation — not just a signature collected by whoever is on site that day. If your practice relies on standing orders or a remote prescriber relationship for any location, build that into the consent workflow explicitly, and don't assume the form alone closes the gap.

Documenting Product, Units, and Areas Consented To

The consent form and the treatment chart record two different moments and shouldn't be confused with each other. The consent form documents what the patient agreed to before the needle goes in: the specific product, the treatment areas, and — where your practice discloses it at this stage — the planned units or a unit range per area. The chart documents what actually happened during the visit: the exact units placed at each injection point, mapped and totaled against the vial log.

A consent form that says "Botox to forehead and glabella" authorizes a category of treatment, not a specific dose. If the plan changes meaningfully once the provider examines the patient — a new area is added, or the areas discussed at consultation turn out to need a different approach — the consent should reflect what was actually agreed to before treatment, not what was originally proposed. Our Botox charting template guide covers what the treatment-day record must capture field by field, including the face map and vial-log reconciliation that consent alone doesn't attempt.

The practical rule: consent sets the boundaries of what's authorized — product and areas, at minimum — and the chart proves what was delivered inside those boundaries. If your chart ever shows an area that isn't named anywhere on the signed consent, you have a documentation gap regardless of how the treatment went.

This matters most at the margins of a treatment plan. A patient consented for glabella and forehead who mentions, mid-visit, that they'd also like something done about crow's feet has not consented to that addition — the conversation about risk and off-label status for that new area still has to happen, and the form still has to reflect it, before the provider injects it. A busy visit is exactly when this step gets skipped, and it's exactly the kind of gap a reviewer looks for first, because the chart will show an area the consent never authorized.

Get the Free Med Spa Compliance Checklist

The full practice-readiness audit — the yes/no checkpoints behind this guide, delivered to your inbox so you can find your gaps before a board does.

No spam. Unsubscribe anytime.

When Do You Need a New Consent? Re-Consent Triggers for Repeat Botox Patients

Best practice is a new signed consent at every treatment episode, not a single consent that's assumed to cover whatever happens going forward. For a repeat neurotoxin patient, a few specific triggers make re-consent necessary even inside that general rule:

  • Product switch. Moving a patient from Botox to Dysport, Xeomin, Jeuveau, or Daxxify changes the dosing units, the risk profile in minor ways, and the product name on the form. The prior consent, naming a different product, doesn't cover the new one.
  • New treatment area. Adding masseter or neck treatment for a patient previously consented only for glabella and forehead is a new off-label disclosure the original form never made.
  • A meaningful time gap. Consent doesn't roll forward indefinitely. A patient returning after a long gap should be treated, for consent purposes, as if the health-history and risk conversation needs to happen again — because it does; health status, medications, and pregnancy status can all have changed.
  • A change in health status or medications. New anticoagulant use, a new pregnancy, or a new neuromuscular diagnosis changes the contraindication picture the original consent screened for.
  • Touch-up vs. new treatment. A touch-up continuing the same treatment plan inside the policy window your form already disclosed is not automatically a new consent event — but it should be noted as a touch-up of a specific prior visit, not charted as if it were a standalone session. A visit outside that window, or one your practice would otherwise bill and plan as a new treatment, needs its own consent.

The underlying principle — that consent documents a specific treatment on a specific date, and doesn't survive a change in what's being proposed — comes from general consent law and is covered at more length in our consent forms guide. What's neurotoxin-specific is the list above: the particular things about a repeat Botox visit that should make you reach for a fresh form rather than relying on the one already in the chart.

Electronic Signatures and Version Control for Neurotoxin Consent

Electronic signatures are legally valid for Botox consent under the same federal and state law that covers every other medical consent form, and our consent forms guide sets out what a defensible e-signature implementation needs — attribution, full disclosure of content before signing, an audit trail, and a business associate agreement with the vendor. We won't repeat that list here.

What deserves specific attention for neurotoxin is version control, because this is the consent form practices edit most often without realizing it. A practice that adds a new product to its menu, starts offering masseter treatment, or changes its touch-up policy has changed what the form needs to say — and if the old version stays live in the e-signature system, patients keep signing a document that doesn't match what's actually being discussed with them.

  • Number and date every version of the Botox consent form, and record which version a given patient signed.
  • When you add a product, an off-label area, or change the touch-up policy, that's a form revision — not a verbal addendum to the existing document.
  • Keep the ability to reproduce the exact version a patient signed on a given date, not just the current template, for as long as you retain the record.
  • If your e-signature platform allows editing a form "in place," turn that off for anything already in use — a true revision needs a new version number, not a silent edit.

The failure pattern to watch for is a practice that trains staff verbally on a policy change — "we're adding neck treatment starting Monday" — without touching the consent form at all. Staff adapt their conversation with patients; the document patients actually sign doesn't change to match. Months later, every patient treated in that window has a signed form that's silent on the exact area now at issue, and the practice's own verbal training record becomes the only evidence of what was disclosed.

How Botox Consent Forms and SOPs Work Together

Consent forms and SOPs are two different documents that serve distinct but complementary purposes:

  • The SOP defines how the treatment is performed — assessment criteria, injection technique, dose guidelines, complication management protocols, and aftercare. It's an internal clinical document that guides your staff.
  • The consent form documents the patient's informed agreement to the specific treatment on a specific date. It's a patient-facing legal document.

They must be consistent with each other. If your SOP says "patients with neuromuscular disease are contraindicated," your consent form's health history checklist must screen for neuromuscular disease. If your SOP includes specific aftercare instructions, those same instructions should be referenced or included in the consent and aftercare document provided to the patient.

A mismatch between your SOP and your consent form — or a gap where the consent doesn't cover a risk your SOP acknowledges — is a significant liability exposure. Botox is one form in a much larger set; our guide to the consent forms every med spa needs maps the full library.

Common Botox Consent Form Mistakes

Missing the FDA Boxed Warning

This is the #1 deficiency in generic consent forms. If your consent doesn't include the Boxed Warning about distant spread of toxin effects, it is legally inadequate.

Using the Same Form for All Neuromodulators

Botox, Dysport, Xeomin, Jeuveau, and Daxxify have different formulations, dosing units, and slightly different risk profiles. Your consent should specify which product is being used — and the same rule applies across the aisle, since a collagen biostimulator like Sculptra needs its own dedicated consent template rather than a neurotoxin form repurposed for it.

Not Naming Off-Label Areas Explicitly

Masseter reduction, neck bands, a gummy smile, and hyperhidrosis outside the labeled sites are common and routine, but they're still off-label use. A form that lists "treatment areas" without flagging which ones fall outside the product's labeled indication hasn't made that disclosure, even if the area itself is named.

No Date or Treatment Area Specificity

A consent form signed months or years ago is not valid documentation for today's treatment. Always use treatment-specific, dated consent forms.

Letting the Form Go Stale as Your Practice Changes

A consent form is a snapshot of your product menu and protocols at the time it was written. Add a product, a treatment area, or a new touch-up policy, and the form that doesn't reflect that change is actively misleading patients about what they're agreeing to — see version control above.

No Attestation That Questions Were Answered

The consent must document that the patient had the opportunity to ask questions — not just that they received the information. Include explicit language: "I have had the opportunity to ask questions, and my questions have been answered to my satisfaction."

Conflating Photo Consent with Treatment Consent

Consent to treatment is separate from consent to use photos for marketing. Many practices blur this line on a single form, which can create HIPAA issues if marketing consent is later disputed — see our consent forms guide for what the marketing authorization has to say on its own.

Is There a Botox Consent Form Template You Can Use?

A template is a starting point, not a compliance outcome. It can get you the structure — the required fields, a clinically complete risk list, a signature architecture that separates patient and practitioner attestation — in a fraction of the time a blank page takes. What it cannot do is know which products you actually inject, which areas you treat off-label, what your touch-up policy is, or which practitioner in your state structure is allowed to obtain the consent. A template used unmodified, carrying another practice's product list and policies, can misrepresent what your practice actually does — which is worse than a shorter form that accurately describes it.

The workable approach: start from a structurally sound template, customize every field that touches your actual products, areas, and policies, and have your medical director and a healthcare attorney licensed in your state review the result before it goes anywhere near a patient. That review step is not optional and not a formality — it's the difference between a form that looks right and one that holds up.

A Botox consent form example found through a generic search is often written for a single product, assumes a single state's delegation rules, and was never reviewed against the Boxed Warning requirement at all. Use it to see what a complete document looks like structurally — then rebuild the content around your own product menu, areas, and state rules rather than adopting it wholesale.

What a Reviewer Checks on a Neurotoxin Consent

When a board investigator, a malpractice carrier, or opposing counsel pulls a Botox chart, the consent form gets read against a short, specific set of questions — separate from the general examiner checklist our consent forms guide covers, because these are the points unique to neurotoxin:

  • Does the form name the specific product injected, not a generic "neurotoxin" or "Botox-type" label?
  • If any treated area is off-label, is that disclosed explicitly rather than folded into a general areas list?
  • Is the FDA Boxed Warning present in full, not summarized or paraphrased down to "may cause side effects"?
  • Does it set a realistic onset and duration expectation, rather than implying an immediate or permanent result?
  • Is the touch-up policy stated, so a follow-up visit isn't a point of dispute over what was promised?
  • Is the practitioner who conducted the consent discussion identified by name and signature, separate from whoever collected the signature?
  • Does the version on file match the product and policy menu the practice was actually running on the date of treatment?

A form that answers all seven cleanly is a materially stronger piece of evidence than one that answers even one of them ambiguously — and unlike clinical outcome, every one of these is entirely within the practice's control before treatment ever happens.

Record Retention for Neurotoxin Consent Forms

Signed Botox consent forms are medical records and follow the same retention rules as every other signed consent in your practice — there's nothing neurotoxin-specific about how long you keep them. Store every signed form in your HIPAA-compliant EHR or document management system, and see our consent forms guide for the full retention schedule, including the separate federal and state clocks that apply and why most practices end up keeping records longer than either one alone requires.

Key Takeaways

  1. Name the specific neurotoxin product on every consent form — never a generic "Botox-type" label
  2. Disclose off-label treatment areas explicitly, by area
  3. Include the FDA Boxed Warning on every Botox consent form — it is a legal requirement
  4. Set onset and duration expectations and state the touch-up policy in writing
  5. Confirm who in your state's delegation structure is permitted to obtain the consent — it may not be the injector
  6. Re-consent at defined triggers: product switch, new area, a meaningful time gap, or a change in health status
  7. Version and date every revision of the form, and keep the ability to reproduce exactly what a patient signed
  8. Treat a downloaded template as a draft — not a finished document — until your medical director and counsel approve it

Consent documents, whatever their source, should be approved by your medical director and reviewed by counsel licensed in your state before use. This article describes general documentation practice; it is not legal or medical advice.

A signed consent only holds up if the person who injected was legally permitted to — the two obligations travel together. For the breakdown by role, prescriber relationship, and state supervision model, see our guide on who can inject Botox in the United States. And for what the treatment itself must show once consent is signed, see our Botox charting template guide.

Last reviewed October 2026. Content is reviewed whenever federal or state regulations change. Written for licensed med spa operators and medical directors.

Frequently Asked Questions

Common questions about Botox consent forms at med spas.

Is informed consent required for Botox injections? + −
Yes, informed consent is legally required for Botox in all U.S. states. Botox is an FDA-approved prescription medication with known risks including a Boxed Warning. Failure to obtain documented informed consent is one of the most common findings in aesthetic malpractice claims. Consent must be signed before treatment, not after.
What risks must be disclosed in a Botox consent form? + −
Required disclosures include: bruising, swelling, headache, asymmetry, ptosis (eyelid drooping), and the FDA Boxed Warning about distant spread of toxin effects including dysphagia, dysphonia, and breathing difficulties. The consent must also disclose that results are temporary, individual outcomes vary, and touch-up treatments may be needed.
How long should Botox consent forms be retained? + −
Medical records including signed consent forms should be retained for a minimum of 7 years for adult patients in most states. Some states require longer retention periods. Store all consent forms in a HIPAA-compliant system with secure backup.
Can patients sign Botox consent forms electronically? + −
Yes. Electronic signatures are legally valid under the E-SIGN Act. You must use a HIPAA-compliant platform that verifies patient identity, captures the specific document signed, and timestamps the signature. Ensure signed documents are stored securely and accessible to the patient on request.
Do I need a new consent form for each Botox treatment? + −
Best practice is to obtain a new signed consent for each treatment session, since treatment areas, doses, and patient health status may change. Most malpractice carriers recommend per-visit consent forms with updated health history and current medications documented at each visit.
Is there a Botox consent form template you can use? + −
A template is a reasonable starting point, not a finished compliance document. It can get the structure right — the product and area fields, the risk list, the signature lines — but it cannot know your state's consent and delegation rules, your specific product mix, or your practice's own protocols. Any template has to be customized to match what you actually inject and how you actually treat, then approved by your medical director and reviewed by counsel before it goes anywhere near a patient.
What should a Botox consent form example include? + −
A usable example shows the specific product name, the treatment areas and whether any are off-label, the FDA Boxed Warning language, the common and rare risks including ptosis and asymmetry, onset and duration expectations, the touch-up policy, contraindication screening, and separate signature lines for the patient and the practitioner who conducted the consent discussion. An example missing the Boxed Warning or using a generic "neurotoxin" label instead of naming the product is incomplete regardless of how polished it looks.

Get a Complete Botox SOP with Consent Templates

Our Injectables Protocol Kit includes a complete Botox SOP with consent templates, pre-treatment assessment, injection protocols, complication management, and aftercare. Professionally written, ready for Medical Director approval.

Get the Injectables Kit — $297
30-Day Money-Back Guarantee